cdcp1 py734 cell signaling technology  (Cell Signaling Technology Inc)


Bioz Verified Symbol Cell Signaling Technology Inc is a verified supplier
Bioz Manufacturer Symbol Cell Signaling Technology Inc manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
    • 92
      Buy from Supplier

    Structured Review

    Cell Signaling Technology Inc cdcp1 py734 cell signaling technology
    Antibodies and Dilutions Used for IHC and Western Blot Analysis
    Cdcp1 Py734 Cell Signaling Technology, supplied by Cell Signaling Technology Inc, used in various techniques. Bioz Stars score: 92/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/cdcp1 py734 cell signaling technology/product/Cell Signaling Technology Inc
    Average 92 stars, based on 1 article reviews
    Price from $9.99 to $1999.99
    cdcp1 py734 cell signaling technology - by Bioz Stars, 2023-06
    92/100 stars

    Images

    1) Product Images from "Src Kinase Is Biphosphorylated at Y416/Y527 and Activates the CUB-Domain Containing Protein 1/Protein Kinase C δ Pathway in a Subset of Triple-Negative Breast Cancers"

    Article Title: Src Kinase Is Biphosphorylated at Y416/Y527 and Activates the CUB-Domain Containing Protein 1/Protein Kinase C δ Pathway in a Subset of Triple-Negative Breast Cancers

    Journal: The American Journal of Pathology

    doi: 10.1016/j.ajpath.2019.10.017

    Antibodies and Dilutions Used for IHC and Western Blot Analysis
    Figure Legend Snippet: Antibodies and Dilutions Used for IHC and Western Blot Analysis

    Techniques Used: Western Blot

    SFK substrates CUB-domain containing protein 1 (CDCP1) and protein kinase C δ (PKCδ) are phosphorylated in SFK_pY416 positive triple-negative breast cancer (TNBC). A: Representative patient sample with diffuse immunohistochemical staining of tumor cells for SFK_pY416, CDCP1_pY743, and PKCä_pY311. Staining for each marker was detected primarily on the cell membrane. Negative cells are predominantly stromal lymphocytes. B: Representative patient sample with a focal/low (<20%) pattern of staining for SFK_pY416, CDCP1_pY743, and PKCä_pY311 in tumor cells. C: Representative patient sample with negative staining. Insets: Areas of interest at higher magnification to show detail. D: Summary of staining results in panel of 56 TNBC samples. Main images were acquired using a 10× objective, and insets were acquired using a 40× objective. Scale bars = 100 μm (A–C). FOXA, forkhead box protein.
    Figure Legend Snippet: SFK substrates CUB-domain containing protein 1 (CDCP1) and protein kinase C δ (PKCδ) are phosphorylated in SFK_pY416 positive triple-negative breast cancer (TNBC). A: Representative patient sample with diffuse immunohistochemical staining of tumor cells for SFK_pY416, CDCP1_pY743, and PKCä_pY311. Staining for each marker was detected primarily on the cell membrane. Negative cells are predominantly stromal lymphocytes. B: Representative patient sample with a focal/low (<20%) pattern of staining for SFK_pY416, CDCP1_pY743, and PKCä_pY311 in tumor cells. C: Representative patient sample with negative staining. Insets: Areas of interest at higher magnification to show detail. D: Summary of staining results in panel of 56 TNBC samples. Main images were acquired using a 10× objective, and insets were acquired using a 40× objective. Scale bars = 100 μm (A–C). FOXA, forkhead box protein.

    Techniques Used: Immunohistochemical staining, Staining, Marker, Negative Staining

    Clinical and Pathologic Features of TNBC Patient Samples in Relation to High (> 20%) SFK_pY416 Expression
    Figure Legend Snippet: Clinical and Pathologic Features of TNBC Patient Samples in Relation to High (> 20%) SFK_pY416 Expression

    Techniques Used:

    SFK_pY416 and SFK_pY527 are co-expressed in triple-negative breast cancer (TNBC). A: Western blot analysis confirms the co-expression of phosphorylated SFK/CUB-domain containing protein 1 (CDCP1) proteins, as determined by immunohistochemistry (IHC), and shows the co-expression of SFK_pY416 and SFK_pY527. Paraffin sections of TNBC were extracted and analyzed by standard Western blot analysis technique. forkhead box protein 1 (FOXA1), vimentin, and SFK_pY416 expression levels in tumor cells, as determined by IHC, are summarized on top. Probing with SFK_pY416 antibody detects a 60-kDa band in all patient samples that were SFK_pY416+ by IHC (lanes 4 and 8 to 13) and does not detect the band in patient samples that were SFK_pY416− by IHC. Cleaved CDCP1_pY734, CDCP1_pY743, and SFK_pY527 are co-expressed with SFK_pY416. Whole cell lysate from the TNBC cell line MDA-MB-231 was used as a positive control (lane 1). TNBC-2 (lane 4) has granular cytoplasmic staining for SFK_pY416. All other SFK_pY416+ tumors had membrane staining. Equal amounts of protein were loaded to each lane, as quantitated by tryptophan fluorescence spectrometry. β-Actin was used as a loading control. B: Analysis of TNBC proteome in silico showing top eight proteins (protein names displayed next to data point) whose expression is correlated with SFK_pY416, with SFK_pY527 exhibiting the strongest correlation. TNBC tumor samples were isolated from The Cancer Proteome Atlas (TCPA) breast cancer (BRCA) data set by negativity for estrogen receptor, progesterone receptor, and human epidermal growth factor 2 receptor and analyzed for correlation of protein markers. Correlations were derived by Pearson product moment correlation test. cCDCP1, cleaved CDCP1; EGFR, epidermal growth factor receptor; FASN, fatty acid synthase; flCDCP1, full-length CDCP1; MEK1, dual specificity mitogen-activated protein kinase kinase 1; NFKBp65, nuclear factor NF-kappa-B p65 subunit; PEA15, astrocytic phosphoprotein PEA-15; RAB25, Ras-related protein rab-25; SFK, Src family kinase; SHP2, Src homology region 2–containing protein tyrosine phosphatase; STAT3, signal transducer and activator of transcription 3.
    Figure Legend Snippet: SFK_pY416 and SFK_pY527 are co-expressed in triple-negative breast cancer (TNBC). A: Western blot analysis confirms the co-expression of phosphorylated SFK/CUB-domain containing protein 1 (CDCP1) proteins, as determined by immunohistochemistry (IHC), and shows the co-expression of SFK_pY416 and SFK_pY527. Paraffin sections of TNBC were extracted and analyzed by standard Western blot analysis technique. forkhead box protein 1 (FOXA1), vimentin, and SFK_pY416 expression levels in tumor cells, as determined by IHC, are summarized on top. Probing with SFK_pY416 antibody detects a 60-kDa band in all patient samples that were SFK_pY416+ by IHC (lanes 4 and 8 to 13) and does not detect the band in patient samples that were SFK_pY416− by IHC. Cleaved CDCP1_pY734, CDCP1_pY743, and SFK_pY527 are co-expressed with SFK_pY416. Whole cell lysate from the TNBC cell line MDA-MB-231 was used as a positive control (lane 1). TNBC-2 (lane 4) has granular cytoplasmic staining for SFK_pY416. All other SFK_pY416+ tumors had membrane staining. Equal amounts of protein were loaded to each lane, as quantitated by tryptophan fluorescence spectrometry. β-Actin was used as a loading control. B: Analysis of TNBC proteome in silico showing top eight proteins (protein names displayed next to data point) whose expression is correlated with SFK_pY416, with SFK_pY527 exhibiting the strongest correlation. TNBC tumor samples were isolated from The Cancer Proteome Atlas (TCPA) breast cancer (BRCA) data set by negativity for estrogen receptor, progesterone receptor, and human epidermal growth factor 2 receptor and analyzed for correlation of protein markers. Correlations were derived by Pearson product moment correlation test. cCDCP1, cleaved CDCP1; EGFR, epidermal growth factor receptor; FASN, fatty acid synthase; flCDCP1, full-length CDCP1; MEK1, dual specificity mitogen-activated protein kinase kinase 1; NFKBp65, nuclear factor NF-kappa-B p65 subunit; PEA15, astrocytic phosphoprotein PEA-15; RAB25, Ras-related protein rab-25; SFK, Src family kinase; SHP2, Src homology region 2–containing protein tyrosine phosphatase; STAT3, signal transducer and activator of transcription 3.

    Techniques Used: Western Blot, Expressing, Immunohistochemistry, Positive Control, Staining, Fluorescence, In Silico, Isolation, Derivative Assay

    Western blot analysis of SFK_pY416− triple-negative breast cancer (TNBC) reveals that forkhead box protein 1 (FOXA1)+ samples tend to be SFK_pY527+ and FOXA1− samples tend to be SFK_pY527−. Paraffin sections of TNBC were extracted and analyzed by standard Western blot analysis technique. FOXA1, vimentin, and SFK_pY416 expression levels in tumor cells, as determined by immunohistochemistry (IHC), are summarized on top. A: All FOXA1+/SFK_pY416− samples tested were SFK_pY527+. The presence of SFK_pY416 in lanes 2, 4, and 6 is due to the presence of SFK_pY416+ lymphocytes in these tumor samples (shown in Supplemental Figure S1). B: Five of six FOXA1−/SFK_pY416− samples tested were SFK_pY527− (lanes 2, 3, and 5 to 7). Three FOXA1−/SFK_pY416+ tumor samples were run as controls. All samples contain phosphorylated AMP-activated protein kinase alpha (AMPKα) as a uniformly phosphorylated control for phosphoprotein extraction. Equal amounts of protein were loaded to each lane, as quantitated by tryptophan fluorescence spectrometry. β-Actin was used as a loading control. cCDCP1, cleaved CDCP1; CDCP1, CUB-domain containing protein 1; flCDCP1, full-length CDCP1; PKC, protein kinase C.
    Figure Legend Snippet: Western blot analysis of SFK_pY416− triple-negative breast cancer (TNBC) reveals that forkhead box protein 1 (FOXA1)+ samples tend to be SFK_pY527+ and FOXA1− samples tend to be SFK_pY527−. Paraffin sections of TNBC were extracted and analyzed by standard Western blot analysis technique. FOXA1, vimentin, and SFK_pY416 expression levels in tumor cells, as determined by immunohistochemistry (IHC), are summarized on top. A: All FOXA1+/SFK_pY416− samples tested were SFK_pY527+. The presence of SFK_pY416 in lanes 2, 4, and 6 is due to the presence of SFK_pY416+ lymphocytes in these tumor samples (shown in Supplemental Figure S1). B: Five of six FOXA1−/SFK_pY416− samples tested were SFK_pY527− (lanes 2, 3, and 5 to 7). Three FOXA1−/SFK_pY416+ tumor samples were run as controls. All samples contain phosphorylated AMP-activated protein kinase alpha (AMPKα) as a uniformly phosphorylated control for phosphoprotein extraction. Equal amounts of protein were loaded to each lane, as quantitated by tryptophan fluorescence spectrometry. β-Actin was used as a loading control. cCDCP1, cleaved CDCP1; CDCP1, CUB-domain containing protein 1; flCDCP1, full-length CDCP1; PKC, protein kinase C.

    Techniques Used: Western Blot, Expressing, Immunohistochemistry, Fluorescence

    cdcp1 py734 cell signaling technology  (Cell Signaling Technology Inc)


    Bioz Verified Symbol Cell Signaling Technology Inc is a verified supplier
    Bioz Manufacturer Symbol Cell Signaling Technology Inc manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
    • 92
      Buy from Supplier

    Structured Review

    Cell Signaling Technology Inc cdcp1 py734 cell signaling technology
    Antibodies and Dilutions Used for IHC and Western Blot Analysis
    Cdcp1 Py734 Cell Signaling Technology, supplied by Cell Signaling Technology Inc, used in various techniques. Bioz Stars score: 92/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/cdcp1 py734 cell signaling technology/product/Cell Signaling Technology Inc
    Average 92 stars, based on 1 article reviews
    Price from $9.99 to $1999.99
    cdcp1 py734 cell signaling technology - by Bioz Stars, 2023-06
    92/100 stars

    Images

    1) Product Images from "Src Kinase Is Biphosphorylated at Y416/Y527 and Activates the CUB-Domain Containing Protein 1/Protein Kinase C δ Pathway in a Subset of Triple-Negative Breast Cancers"

    Article Title: Src Kinase Is Biphosphorylated at Y416/Y527 and Activates the CUB-Domain Containing Protein 1/Protein Kinase C δ Pathway in a Subset of Triple-Negative Breast Cancers

    Journal: The American Journal of Pathology

    doi: 10.1016/j.ajpath.2019.10.017

    Antibodies and Dilutions Used for IHC and Western Blot Analysis
    Figure Legend Snippet: Antibodies and Dilutions Used for IHC and Western Blot Analysis

    Techniques Used: Western Blot

    SFK substrates CUB-domain containing protein 1 (CDCP1) and protein kinase C δ (PKCδ) are phosphorylated in SFK_pY416 positive triple-negative breast cancer (TNBC). A: Representative patient sample with diffuse immunohistochemical staining of tumor cells for SFK_pY416, CDCP1_pY743, and PKCä_pY311. Staining for each marker was detected primarily on the cell membrane. Negative cells are predominantly stromal lymphocytes. B: Representative patient sample with a focal/low (<20%) pattern of staining for SFK_pY416, CDCP1_pY743, and PKCä_pY311 in tumor cells. C: Representative patient sample with negative staining. Insets: Areas of interest at higher magnification to show detail. D: Summary of staining results in panel of 56 TNBC samples. Main images were acquired using a 10× objective, and insets were acquired using a 40× objective. Scale bars = 100 μm (A–C). FOXA, forkhead box protein.
    Figure Legend Snippet: SFK substrates CUB-domain containing protein 1 (CDCP1) and protein kinase C δ (PKCδ) are phosphorylated in SFK_pY416 positive triple-negative breast cancer (TNBC). A: Representative patient sample with diffuse immunohistochemical staining of tumor cells for SFK_pY416, CDCP1_pY743, and PKCä_pY311. Staining for each marker was detected primarily on the cell membrane. Negative cells are predominantly stromal lymphocytes. B: Representative patient sample with a focal/low (<20%) pattern of staining for SFK_pY416, CDCP1_pY743, and PKCä_pY311 in tumor cells. C: Representative patient sample with negative staining. Insets: Areas of interest at higher magnification to show detail. D: Summary of staining results in panel of 56 TNBC samples. Main images were acquired using a 10× objective, and insets were acquired using a 40× objective. Scale bars = 100 μm (A–C). FOXA, forkhead box protein.

    Techniques Used: Immunohistochemical staining, Staining, Marker, Negative Staining

    Clinical and Pathologic Features of TNBC Patient Samples in Relation to High (> 20%) SFK_pY416 Expression
    Figure Legend Snippet: Clinical and Pathologic Features of TNBC Patient Samples in Relation to High (> 20%) SFK_pY416 Expression

    Techniques Used:

    SFK_pY416 and SFK_pY527 are co-expressed in triple-negative breast cancer (TNBC). A: Western blot analysis confirms the co-expression of phosphorylated SFK/CUB-domain containing protein 1 (CDCP1) proteins, as determined by immunohistochemistry (IHC), and shows the co-expression of SFK_pY416 and SFK_pY527. Paraffin sections of TNBC were extracted and analyzed by standard Western blot analysis technique. forkhead box protein 1 (FOXA1), vimentin, and SFK_pY416 expression levels in tumor cells, as determined by IHC, are summarized on top. Probing with SFK_pY416 antibody detects a 60-kDa band in all patient samples that were SFK_pY416+ by IHC (lanes 4 and 8 to 13) and does not detect the band in patient samples that were SFK_pY416− by IHC. Cleaved CDCP1_pY734, CDCP1_pY743, and SFK_pY527 are co-expressed with SFK_pY416. Whole cell lysate from the TNBC cell line MDA-MB-231 was used as a positive control (lane 1). TNBC-2 (lane 4) has granular cytoplasmic staining for SFK_pY416. All other SFK_pY416+ tumors had membrane staining. Equal amounts of protein were loaded to each lane, as quantitated by tryptophan fluorescence spectrometry. β-Actin was used as a loading control. B: Analysis of TNBC proteome in silico showing top eight proteins (protein names displayed next to data point) whose expression is correlated with SFK_pY416, with SFK_pY527 exhibiting the strongest correlation. TNBC tumor samples were isolated from The Cancer Proteome Atlas (TCPA) breast cancer (BRCA) data set by negativity for estrogen receptor, progesterone receptor, and human epidermal growth factor 2 receptor and analyzed for correlation of protein markers. Correlations were derived by Pearson product moment correlation test. cCDCP1, cleaved CDCP1; EGFR, epidermal growth factor receptor; FASN, fatty acid synthase; flCDCP1, full-length CDCP1; MEK1, dual specificity mitogen-activated protein kinase kinase 1; NFKBp65, nuclear factor NF-kappa-B p65 subunit; PEA15, astrocytic phosphoprotein PEA-15; RAB25, Ras-related protein rab-25; SFK, Src family kinase; SHP2, Src homology region 2–containing protein tyrosine phosphatase; STAT3, signal transducer and activator of transcription 3.
    Figure Legend Snippet: SFK_pY416 and SFK_pY527 are co-expressed in triple-negative breast cancer (TNBC). A: Western blot analysis confirms the co-expression of phosphorylated SFK/CUB-domain containing protein 1 (CDCP1) proteins, as determined by immunohistochemistry (IHC), and shows the co-expression of SFK_pY416 and SFK_pY527. Paraffin sections of TNBC were extracted and analyzed by standard Western blot analysis technique. forkhead box protein 1 (FOXA1), vimentin, and SFK_pY416 expression levels in tumor cells, as determined by IHC, are summarized on top. Probing with SFK_pY416 antibody detects a 60-kDa band in all patient samples that were SFK_pY416+ by IHC (lanes 4 and 8 to 13) and does not detect the band in patient samples that were SFK_pY416− by IHC. Cleaved CDCP1_pY734, CDCP1_pY743, and SFK_pY527 are co-expressed with SFK_pY416. Whole cell lysate from the TNBC cell line MDA-MB-231 was used as a positive control (lane 1). TNBC-2 (lane 4) has granular cytoplasmic staining for SFK_pY416. All other SFK_pY416+ tumors had membrane staining. Equal amounts of protein were loaded to each lane, as quantitated by tryptophan fluorescence spectrometry. β-Actin was used as a loading control. B: Analysis of TNBC proteome in silico showing top eight proteins (protein names displayed next to data point) whose expression is correlated with SFK_pY416, with SFK_pY527 exhibiting the strongest correlation. TNBC tumor samples were isolated from The Cancer Proteome Atlas (TCPA) breast cancer (BRCA) data set by negativity for estrogen receptor, progesterone receptor, and human epidermal growth factor 2 receptor and analyzed for correlation of protein markers. Correlations were derived by Pearson product moment correlation test. cCDCP1, cleaved CDCP1; EGFR, epidermal growth factor receptor; FASN, fatty acid synthase; flCDCP1, full-length CDCP1; MEK1, dual specificity mitogen-activated protein kinase kinase 1; NFKBp65, nuclear factor NF-kappa-B p65 subunit; PEA15, astrocytic phosphoprotein PEA-15; RAB25, Ras-related protein rab-25; SFK, Src family kinase; SHP2, Src homology region 2–containing protein tyrosine phosphatase; STAT3, signal transducer and activator of transcription 3.

    Techniques Used: Western Blot, Expressing, Immunohistochemistry, Positive Control, Staining, Fluorescence, In Silico, Isolation, Derivative Assay

    Western blot analysis of SFK_pY416− triple-negative breast cancer (TNBC) reveals that forkhead box protein 1 (FOXA1)+ samples tend to be SFK_pY527+ and FOXA1− samples tend to be SFK_pY527−. Paraffin sections of TNBC were extracted and analyzed by standard Western blot analysis technique. FOXA1, vimentin, and SFK_pY416 expression levels in tumor cells, as determined by immunohistochemistry (IHC), are summarized on top. A: All FOXA1+/SFK_pY416− samples tested were SFK_pY527+. The presence of SFK_pY416 in lanes 2, 4, and 6 is due to the presence of SFK_pY416+ lymphocytes in these tumor samples (shown in Supplemental Figure S1). B: Five of six FOXA1−/SFK_pY416− samples tested were SFK_pY527− (lanes 2, 3, and 5 to 7). Three FOXA1−/SFK_pY416+ tumor samples were run as controls. All samples contain phosphorylated AMP-activated protein kinase alpha (AMPKα) as a uniformly phosphorylated control for phosphoprotein extraction. Equal amounts of protein were loaded to each lane, as quantitated by tryptophan fluorescence spectrometry. β-Actin was used as a loading control. cCDCP1, cleaved CDCP1; CDCP1, CUB-domain containing protein 1; flCDCP1, full-length CDCP1; PKC, protein kinase C.
    Figure Legend Snippet: Western blot analysis of SFK_pY416− triple-negative breast cancer (TNBC) reveals that forkhead box protein 1 (FOXA1)+ samples tend to be SFK_pY527+ and FOXA1− samples tend to be SFK_pY527−. Paraffin sections of TNBC were extracted and analyzed by standard Western blot analysis technique. FOXA1, vimentin, and SFK_pY416 expression levels in tumor cells, as determined by immunohistochemistry (IHC), are summarized on top. A: All FOXA1+/SFK_pY416− samples tested were SFK_pY527+. The presence of SFK_pY416 in lanes 2, 4, and 6 is due to the presence of SFK_pY416+ lymphocytes in these tumor samples (shown in Supplemental Figure S1). B: Five of six FOXA1−/SFK_pY416− samples tested were SFK_pY527− (lanes 2, 3, and 5 to 7). Three FOXA1−/SFK_pY416+ tumor samples were run as controls. All samples contain phosphorylated AMP-activated protein kinase alpha (AMPKα) as a uniformly phosphorylated control for phosphoprotein extraction. Equal amounts of protein were loaded to each lane, as quantitated by tryptophan fluorescence spectrometry. β-Actin was used as a loading control. cCDCP1, cleaved CDCP1; CDCP1, CUB-domain containing protein 1; flCDCP1, full-length CDCP1; PKC, protein kinase C.

    Techniques Used: Western Blot, Expressing, Immunohistochemistry, Fluorescence

    cdcp1 py734 cell signaling technology  (Cell Signaling Technology Inc)


    Bioz Verified Symbol Cell Signaling Technology Inc is a verified supplier
    Bioz Manufacturer Symbol Cell Signaling Technology Inc manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
    • 92
      Buy from Supplier

    Structured Review

    Cell Signaling Technology Inc cdcp1 py734 cell signaling technology
    Antibodies and Dilutions Used for IHC and Western Blot Analysis
    Cdcp1 Py734 Cell Signaling Technology, supplied by Cell Signaling Technology Inc, used in various techniques. Bioz Stars score: 92/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/cdcp1 py734 cell signaling technology/product/Cell Signaling Technology Inc
    Average 92 stars, based on 1 article reviews
    Price from $9.99 to $1999.99
    cdcp1 py734 cell signaling technology - by Bioz Stars, 2023-06
    92/100 stars

    Images

    1) Product Images from "Src Kinase Is Biphosphorylated at Y416/Y527 and Activates the CUB-Domain Containing Protein 1/Protein Kinase C δ Pathway in a Subset of Triple-Negative Breast Cancers"

    Article Title: Src Kinase Is Biphosphorylated at Y416/Y527 and Activates the CUB-Domain Containing Protein 1/Protein Kinase C δ Pathway in a Subset of Triple-Negative Breast Cancers

    Journal: The American Journal of Pathology

    doi: 10.1016/j.ajpath.2019.10.017

    Antibodies and Dilutions Used for IHC and Western Blot Analysis
    Figure Legend Snippet: Antibodies and Dilutions Used for IHC and Western Blot Analysis

    Techniques Used: Western Blot

    SFK substrates CUB-domain containing protein 1 (CDCP1) and protein kinase C δ (PKCδ) are phosphorylated in SFK_pY416 positive triple-negative breast cancer (TNBC). A: Representative patient sample with diffuse immunohistochemical staining of tumor cells for SFK_pY416, CDCP1_pY743, and PKCä_pY311. Staining for each marker was detected primarily on the cell membrane. Negative cells are predominantly stromal lymphocytes. B: Representative patient sample with a focal/low (<20%) pattern of staining for SFK_pY416, CDCP1_pY743, and PKCä_pY311 in tumor cells. C: Representative patient sample with negative staining. Insets: Areas of interest at higher magnification to show detail. D: Summary of staining results in panel of 56 TNBC samples. Main images were acquired using a 10× objective, and insets were acquired using a 40× objective. Scale bars = 100 μm (A–C). FOXA, forkhead box protein.
    Figure Legend Snippet: SFK substrates CUB-domain containing protein 1 (CDCP1) and protein kinase C δ (PKCδ) are phosphorylated in SFK_pY416 positive triple-negative breast cancer (TNBC). A: Representative patient sample with diffuse immunohistochemical staining of tumor cells for SFK_pY416, CDCP1_pY743, and PKCä_pY311. Staining for each marker was detected primarily on the cell membrane. Negative cells are predominantly stromal lymphocytes. B: Representative patient sample with a focal/low (<20%) pattern of staining for SFK_pY416, CDCP1_pY743, and PKCä_pY311 in tumor cells. C: Representative patient sample with negative staining. Insets: Areas of interest at higher magnification to show detail. D: Summary of staining results in panel of 56 TNBC samples. Main images were acquired using a 10× objective, and insets were acquired using a 40× objective. Scale bars = 100 μm (A–C). FOXA, forkhead box protein.

    Techniques Used: Immunohistochemical staining, Staining, Marker, Negative Staining

    Clinical and Pathologic Features of TNBC Patient Samples in Relation to High (> 20%) SFK_pY416 Expression
    Figure Legend Snippet: Clinical and Pathologic Features of TNBC Patient Samples in Relation to High (> 20%) SFK_pY416 Expression

    Techniques Used:

    SFK_pY416 and SFK_pY527 are co-expressed in triple-negative breast cancer (TNBC). A: Western blot analysis confirms the co-expression of phosphorylated SFK/CUB-domain containing protein 1 (CDCP1) proteins, as determined by immunohistochemistry (IHC), and shows the co-expression of SFK_pY416 and SFK_pY527. Paraffin sections of TNBC were extracted and analyzed by standard Western blot analysis technique. forkhead box protein 1 (FOXA1), vimentin, and SFK_pY416 expression levels in tumor cells, as determined by IHC, are summarized on top. Probing with SFK_pY416 antibody detects a 60-kDa band in all patient samples that were SFK_pY416+ by IHC (lanes 4 and 8 to 13) and does not detect the band in patient samples that were SFK_pY416− by IHC. Cleaved CDCP1_pY734, CDCP1_pY743, and SFK_pY527 are co-expressed with SFK_pY416. Whole cell lysate from the TNBC cell line MDA-MB-231 was used as a positive control (lane 1). TNBC-2 (lane 4) has granular cytoplasmic staining for SFK_pY416. All other SFK_pY416+ tumors had membrane staining. Equal amounts of protein were loaded to each lane, as quantitated by tryptophan fluorescence spectrometry. β-Actin was used as a loading control. B: Analysis of TNBC proteome in silico showing top eight proteins (protein names displayed next to data point) whose expression is correlated with SFK_pY416, with SFK_pY527 exhibiting the strongest correlation. TNBC tumor samples were isolated from The Cancer Proteome Atlas (TCPA) breast cancer (BRCA) data set by negativity for estrogen receptor, progesterone receptor, and human epidermal growth factor 2 receptor and analyzed for correlation of protein markers. Correlations were derived by Pearson product moment correlation test. cCDCP1, cleaved CDCP1; EGFR, epidermal growth factor receptor; FASN, fatty acid synthase; flCDCP1, full-length CDCP1; MEK1, dual specificity mitogen-activated protein kinase kinase 1; NFKBp65, nuclear factor NF-kappa-B p65 subunit; PEA15, astrocytic phosphoprotein PEA-15; RAB25, Ras-related protein rab-25; SFK, Src family kinase; SHP2, Src homology region 2–containing protein tyrosine phosphatase; STAT3, signal transducer and activator of transcription 3.
    Figure Legend Snippet: SFK_pY416 and SFK_pY527 are co-expressed in triple-negative breast cancer (TNBC). A: Western blot analysis confirms the co-expression of phosphorylated SFK/CUB-domain containing protein 1 (CDCP1) proteins, as determined by immunohistochemistry (IHC), and shows the co-expression of SFK_pY416 and SFK_pY527. Paraffin sections of TNBC were extracted and analyzed by standard Western blot analysis technique. forkhead box protein 1 (FOXA1), vimentin, and SFK_pY416 expression levels in tumor cells, as determined by IHC, are summarized on top. Probing with SFK_pY416 antibody detects a 60-kDa band in all patient samples that were SFK_pY416+ by IHC (lanes 4 and 8 to 13) and does not detect the band in patient samples that were SFK_pY416− by IHC. Cleaved CDCP1_pY734, CDCP1_pY743, and SFK_pY527 are co-expressed with SFK_pY416. Whole cell lysate from the TNBC cell line MDA-MB-231 was used as a positive control (lane 1). TNBC-2 (lane 4) has granular cytoplasmic staining for SFK_pY416. All other SFK_pY416+ tumors had membrane staining. Equal amounts of protein were loaded to each lane, as quantitated by tryptophan fluorescence spectrometry. β-Actin was used as a loading control. B: Analysis of TNBC proteome in silico showing top eight proteins (protein names displayed next to data point) whose expression is correlated with SFK_pY416, with SFK_pY527 exhibiting the strongest correlation. TNBC tumor samples were isolated from The Cancer Proteome Atlas (TCPA) breast cancer (BRCA) data set by negativity for estrogen receptor, progesterone receptor, and human epidermal growth factor 2 receptor and analyzed for correlation of protein markers. Correlations were derived by Pearson product moment correlation test. cCDCP1, cleaved CDCP1; EGFR, epidermal growth factor receptor; FASN, fatty acid synthase; flCDCP1, full-length CDCP1; MEK1, dual specificity mitogen-activated protein kinase kinase 1; NFKBp65, nuclear factor NF-kappa-B p65 subunit; PEA15, astrocytic phosphoprotein PEA-15; RAB25, Ras-related protein rab-25; SFK, Src family kinase; SHP2, Src homology region 2–containing protein tyrosine phosphatase; STAT3, signal transducer and activator of transcription 3.

    Techniques Used: Western Blot, Expressing, Immunohistochemistry, Positive Control, Staining, Fluorescence, In Silico, Isolation, Derivative Assay

    Western blot analysis of SFK_pY416− triple-negative breast cancer (TNBC) reveals that forkhead box protein 1 (FOXA1)+ samples tend to be SFK_pY527+ and FOXA1− samples tend to be SFK_pY527−. Paraffin sections of TNBC were extracted and analyzed by standard Western blot analysis technique. FOXA1, vimentin, and SFK_pY416 expression levels in tumor cells, as determined by immunohistochemistry (IHC), are summarized on top. A: All FOXA1+/SFK_pY416− samples tested were SFK_pY527+. The presence of SFK_pY416 in lanes 2, 4, and 6 is due to the presence of SFK_pY416+ lymphocytes in these tumor samples (shown in Supplemental Figure S1). B: Five of six FOXA1−/SFK_pY416− samples tested were SFK_pY527− (lanes 2, 3, and 5 to 7). Three FOXA1−/SFK_pY416+ tumor samples were run as controls. All samples contain phosphorylated AMP-activated protein kinase alpha (AMPKα) as a uniformly phosphorylated control for phosphoprotein extraction. Equal amounts of protein were loaded to each lane, as quantitated by tryptophan fluorescence spectrometry. β-Actin was used as a loading control. cCDCP1, cleaved CDCP1; CDCP1, CUB-domain containing protein 1; flCDCP1, full-length CDCP1; PKC, protein kinase C.
    Figure Legend Snippet: Western blot analysis of SFK_pY416− triple-negative breast cancer (TNBC) reveals that forkhead box protein 1 (FOXA1)+ samples tend to be SFK_pY527+ and FOXA1− samples tend to be SFK_pY527−. Paraffin sections of TNBC were extracted and analyzed by standard Western blot analysis technique. FOXA1, vimentin, and SFK_pY416 expression levels in tumor cells, as determined by immunohistochemistry (IHC), are summarized on top. A: All FOXA1+/SFK_pY416− samples tested were SFK_pY527+. The presence of SFK_pY416 in lanes 2, 4, and 6 is due to the presence of SFK_pY416+ lymphocytes in these tumor samples (shown in Supplemental Figure S1). B: Five of six FOXA1−/SFK_pY416− samples tested were SFK_pY527− (lanes 2, 3, and 5 to 7). Three FOXA1−/SFK_pY416+ tumor samples were run as controls. All samples contain phosphorylated AMP-activated protein kinase alpha (AMPKα) as a uniformly phosphorylated control for phosphoprotein extraction. Equal amounts of protein were loaded to each lane, as quantitated by tryptophan fluorescence spectrometry. β-Actin was used as a loading control. cCDCP1, cleaved CDCP1; CDCP1, CUB-domain containing protein 1; flCDCP1, full-length CDCP1; PKC, protein kinase C.

    Techniques Used: Western Blot, Expressing, Immunohistochemistry, Fluorescence

    Similar Products

  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
    • cdcp1 py734 cell signaling technology  (Cell Signaling Technology Inc)
    92
    Cell Signaling Technology Inc cdcp1 py734 cell signaling technology
    Antibodies and Dilutions Used for IHC and Western Blot Analysis
    Cdcp1 Py734 Cell Signaling Technology, supplied by Cell Signaling Technology Inc, used in various techniques. Bioz Stars score: 92/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/cdcp1 py734 cell signaling technology/product/Cell Signaling Technology Inc
    Average 92 stars, based on 1 article reviews
    Price from $9.99 to $1999.99
    cdcp1 py734 cell signaling technology - by Bioz Stars, 2023-06
    92/100 stars
    		  Buy from Supplier

    Image Search Results


    Antibodies and Dilutions Used for IHC and Western Blot Analysis

    Journal: The American Journal of Pathology

    Article Title: Src Kinase Is Biphosphorylated at Y416/Y527 and Activates the CUB-Domain Containing Protein 1/Protein Kinase C δ Pathway in a Subset of Triple-Negative Breast Cancers

    doi: 10.1016/j.ajpath.2019.10.017

    Figure Lengend Snippet: Antibodies and Dilutions Used for IHC and Western Blot Analysis

    Article Snippet: Antibody dilutions for each method are listed in . table ft1 table-wrap mode="anchored" t5 caption a7 Antigen Antibody information, manufacturer/catalog no. Western blot dilution IHC dilution Antigen retrieval ∗ FOXA1 Abcam/ab173287 NA 1:4000 1 Vimentin Agilent/M0725 NA 1:2000 2 Sox10 Bio SB/BSB2583 NA 1:100 1 CK5/6 Thermo Fisher Scientific/180267 NA 1:50 2 CDCP1 Cell Signaling Technology/4115 1:1000 1:100 1 CDCP1_pY743 Cell Signaling Technology/14965 1:1000 1:800 1 CDCP1_pY734 Cell Signaling Technology/9050 1:1000 NA NA Src Cell Signaling Technology/2108 1:1000 NA NA Lck Cell Signaling Technology/2752 1:1000 NA NA Lyn Cell Signaling Technology/2732 1:1000 NA NA SFK_pY416 Cell Signaling Technology/2101 1:1000 1:200 1 SFK_pY527 Cell Signaling Technology/2105 1:1000 NA NA PKCδ Cell Signaling Technology/2058 1:1000 NA NA PKCδ_pY311 Abcam/ab76181 1:2500 1:3000 1 N-cadherin Cell Signaling Technology/13116 NA 1:200 1 Slug Cell Signaling Technology/9585 NA 1:100 1 AMPKα Cell Signaling Technology/2532 1:1000 NA NA AMPKα_pT172 Cell Signaling Technology/2535 1:1000 NA NA β-Actin Leica Biosystems/A5441 1:5000 NA NA CD3 Novocastra/NCL-L-CD3-565 NA 1:50 2 PD1 Cell Signaling Technology/86163 NA 1:200 2 PD-L1 Cell Signaling Technology/13684 NA 1:400 2 CTLA4 Santa Cruz Biotechnology/sc-376016 NA 1:400 2 Open in a separate window AMPK, AMP-activated protein kinase; CDCP, CUB-domain containing protein; CK5/6, cytokeratin 5/6; CTLA4, cytotoxic T-lymphocyte protein 4; FOXA1, forkhead box protein A1; IHC, immunohistochemistry; Lck, tyrosine-protein kinase Lck; Lyn, tyrosine-protein kinase Lyn; NA, not applicable; PD1, programmed cell death protein 1; PD-L1, programmed cell death 1 ligand 1; PKC, protein kinase C; Sox10, Sry-box transcription factor 10.

    Techniques: Western Blot

    SFK substrates CUB-domain containing protein 1 (CDCP1) and protein kinase C δ (PKCδ) are phosphorylated in SFK_pY416 positive triple-negative breast cancer (TNBC). A: Representative patient sample with diffuse immunohistochemical staining of tumor cells for SFK_pY416, CDCP1_pY743, and PKCä_pY311. Staining for each marker was detected primarily on the cell membrane. Negative cells are predominantly stromal lymphocytes. B: Representative patient sample with a focal/low (<20%) pattern of staining for SFK_pY416, CDCP1_pY743, and PKCä_pY311 in tumor cells. C: Representative patient sample with negative staining. Insets: Areas of interest at higher magnification to show detail. D: Summary of staining results in panel of 56 TNBC samples. Main images were acquired using a 10× objective, and insets were acquired using a 40× objective. Scale bars = 100 μm (A–C). FOXA, forkhead box protein.

    Journal: The American Journal of Pathology

    Article Title: Src Kinase Is Biphosphorylated at Y416/Y527 and Activates the CUB-Domain Containing Protein 1/Protein Kinase C δ Pathway in a Subset of Triple-Negative Breast Cancers

    doi: 10.1016/j.ajpath.2019.10.017

    Figure Lengend Snippet: SFK substrates CUB-domain containing protein 1 (CDCP1) and protein kinase C δ (PKCδ) are phosphorylated in SFK_pY416 positive triple-negative breast cancer (TNBC). A: Representative patient sample with diffuse immunohistochemical staining of tumor cells for SFK_pY416, CDCP1_pY743, and PKCä_pY311. Staining for each marker was detected primarily on the cell membrane. Negative cells are predominantly stromal lymphocytes. B: Representative patient sample with a focal/low (<20%) pattern of staining for SFK_pY416, CDCP1_pY743, and PKCä_pY311 in tumor cells. C: Representative patient sample with negative staining. Insets: Areas of interest at higher magnification to show detail. D: Summary of staining results in panel of 56 TNBC samples. Main images were acquired using a 10× objective, and insets were acquired using a 40× objective. Scale bars = 100 μm (A–C). FOXA, forkhead box protein.

    Article Snippet: Antibody dilutions for each method are listed in . table ft1 table-wrap mode="anchored" t5 caption a7 Antigen Antibody information, manufacturer/catalog no. Western blot dilution IHC dilution Antigen retrieval ∗ FOXA1 Abcam/ab173287 NA 1:4000 1 Vimentin Agilent/M0725 NA 1:2000 2 Sox10 Bio SB/BSB2583 NA 1:100 1 CK5/6 Thermo Fisher Scientific/180267 NA 1:50 2 CDCP1 Cell Signaling Technology/4115 1:1000 1:100 1 CDCP1_pY743 Cell Signaling Technology/14965 1:1000 1:800 1 CDCP1_pY734 Cell Signaling Technology/9050 1:1000 NA NA Src Cell Signaling Technology/2108 1:1000 NA NA Lck Cell Signaling Technology/2752 1:1000 NA NA Lyn Cell Signaling Technology/2732 1:1000 NA NA SFK_pY416 Cell Signaling Technology/2101 1:1000 1:200 1 SFK_pY527 Cell Signaling Technology/2105 1:1000 NA NA PKCδ Cell Signaling Technology/2058 1:1000 NA NA PKCδ_pY311 Abcam/ab76181 1:2500 1:3000 1 N-cadherin Cell Signaling Technology/13116 NA 1:200 1 Slug Cell Signaling Technology/9585 NA 1:100 1 AMPKα Cell Signaling Technology/2532 1:1000 NA NA AMPKα_pT172 Cell Signaling Technology/2535 1:1000 NA NA β-Actin Leica Biosystems/A5441 1:5000 NA NA CD3 Novocastra/NCL-L-CD3-565 NA 1:50 2 PD1 Cell Signaling Technology/86163 NA 1:200 2 PD-L1 Cell Signaling Technology/13684 NA 1:400 2 CTLA4 Santa Cruz Biotechnology/sc-376016 NA 1:400 2 Open in a separate window AMPK, AMP-activated protein kinase; CDCP, CUB-domain containing protein; CK5/6, cytokeratin 5/6; CTLA4, cytotoxic T-lymphocyte protein 4; FOXA1, forkhead box protein A1; IHC, immunohistochemistry; Lck, tyrosine-protein kinase Lck; Lyn, tyrosine-protein kinase Lyn; NA, not applicable; PD1, programmed cell death protein 1; PD-L1, programmed cell death 1 ligand 1; PKC, protein kinase C; Sox10, Sry-box transcription factor 10.

    Techniques: Immunohistochemical staining, Staining, Marker, Negative Staining

    Clinical and Pathologic Features of TNBC Patient Samples in Relation to High (> 20%) SFK_pY416 Expression

    Journal: The American Journal of Pathology

    Article Title: Src Kinase Is Biphosphorylated at Y416/Y527 and Activates the CUB-Domain Containing Protein 1/Protein Kinase C δ Pathway in a Subset of Triple-Negative Breast Cancers

    doi: 10.1016/j.ajpath.2019.10.017

    Figure Lengend Snippet: Clinical and Pathologic Features of TNBC Patient Samples in Relation to High (> 20%) SFK_pY416 Expression

    Article Snippet: Antibody dilutions for each method are listed in . table ft1 table-wrap mode="anchored" t5 caption a7 Antigen Antibody information, manufacturer/catalog no. Western blot dilution IHC dilution Antigen retrieval ∗ FOXA1 Abcam/ab173287 NA 1:4000 1 Vimentin Agilent/M0725 NA 1:2000 2 Sox10 Bio SB/BSB2583 NA 1:100 1 CK5/6 Thermo Fisher Scientific/180267 NA 1:50 2 CDCP1 Cell Signaling Technology/4115 1:1000 1:100 1 CDCP1_pY743 Cell Signaling Technology/14965 1:1000 1:800 1 CDCP1_pY734 Cell Signaling Technology/9050 1:1000 NA NA Src Cell Signaling Technology/2108 1:1000 NA NA Lck Cell Signaling Technology/2752 1:1000 NA NA Lyn Cell Signaling Technology/2732 1:1000 NA NA SFK_pY416 Cell Signaling Technology/2101 1:1000 1:200 1 SFK_pY527 Cell Signaling Technology/2105 1:1000 NA NA PKCδ Cell Signaling Technology/2058 1:1000 NA NA PKCδ_pY311 Abcam/ab76181 1:2500 1:3000 1 N-cadherin Cell Signaling Technology/13116 NA 1:200 1 Slug Cell Signaling Technology/9585 NA 1:100 1 AMPKα Cell Signaling Technology/2532 1:1000 NA NA AMPKα_pT172 Cell Signaling Technology/2535 1:1000 NA NA β-Actin Leica Biosystems/A5441 1:5000 NA NA CD3 Novocastra/NCL-L-CD3-565 NA 1:50 2 PD1 Cell Signaling Technology/86163 NA 1:200 2 PD-L1 Cell Signaling Technology/13684 NA 1:400 2 CTLA4 Santa Cruz Biotechnology/sc-376016 NA 1:400 2 Open in a separate window AMPK, AMP-activated protein kinase; CDCP, CUB-domain containing protein; CK5/6, cytokeratin 5/6; CTLA4, cytotoxic T-lymphocyte protein 4; FOXA1, forkhead box protein A1; IHC, immunohistochemistry; Lck, tyrosine-protein kinase Lck; Lyn, tyrosine-protein kinase Lyn; NA, not applicable; PD1, programmed cell death protein 1; PD-L1, programmed cell death 1 ligand 1; PKC, protein kinase C; Sox10, Sry-box transcription factor 10.

    Techniques:

    SFK_pY416 and SFK_pY527 are co-expressed in triple-negative breast cancer (TNBC). A: Western blot analysis confirms the co-expression of phosphorylated SFK/CUB-domain containing protein 1 (CDCP1) proteins, as determined by immunohistochemistry (IHC), and shows the co-expression of SFK_pY416 and SFK_pY527. Paraffin sections of TNBC were extracted and analyzed by standard Western blot analysis technique. forkhead box protein 1 (FOXA1), vimentin, and SFK_pY416 expression levels in tumor cells, as determined by IHC, are summarized on top. Probing with SFK_pY416 antibody detects a 60-kDa band in all patient samples that were SFK_pY416+ by IHC (lanes 4 and 8 to 13) and does not detect the band in patient samples that were SFK_pY416− by IHC. Cleaved CDCP1_pY734, CDCP1_pY743, and SFK_pY527 are co-expressed with SFK_pY416. Whole cell lysate from the TNBC cell line MDA-MB-231 was used as a positive control (lane 1). TNBC-2 (lane 4) has granular cytoplasmic staining for SFK_pY416. All other SFK_pY416+ tumors had membrane staining. Equal amounts of protein were loaded to each lane, as quantitated by tryptophan fluorescence spectrometry. β-Actin was used as a loading control. B: Analysis of TNBC proteome in silico showing top eight proteins (protein names displayed next to data point) whose expression is correlated with SFK_pY416, with SFK_pY527 exhibiting the strongest correlation. TNBC tumor samples were isolated from The Cancer Proteome Atlas (TCPA) breast cancer (BRCA) data set by negativity for estrogen receptor, progesterone receptor, and human epidermal growth factor 2 receptor and analyzed for correlation of protein markers. Correlations were derived by Pearson product moment correlation test. cCDCP1, cleaved CDCP1; EGFR, epidermal growth factor receptor; FASN, fatty acid synthase; flCDCP1, full-length CDCP1; MEK1, dual specificity mitogen-activated protein kinase kinase 1; NFKBp65, nuclear factor NF-kappa-B p65 subunit; PEA15, astrocytic phosphoprotein PEA-15; RAB25, Ras-related protein rab-25; SFK, Src family kinase; SHP2, Src homology region 2–containing protein tyrosine phosphatase; STAT3, signal transducer and activator of transcription 3.

    Journal: The American Journal of Pathology

    Article Title: Src Kinase Is Biphosphorylated at Y416/Y527 and Activates the CUB-Domain Containing Protein 1/Protein Kinase C δ Pathway in a Subset of Triple-Negative Breast Cancers

    doi: 10.1016/j.ajpath.2019.10.017

    Figure Lengend Snippet: SFK_pY416 and SFK_pY527 are co-expressed in triple-negative breast cancer (TNBC). A: Western blot analysis confirms the co-expression of phosphorylated SFK/CUB-domain containing protein 1 (CDCP1) proteins, as determined by immunohistochemistry (IHC), and shows the co-expression of SFK_pY416 and SFK_pY527. Paraffin sections of TNBC were extracted and analyzed by standard Western blot analysis technique. forkhead box protein 1 (FOXA1), vimentin, and SFK_pY416 expression levels in tumor cells, as determined by IHC, are summarized on top. Probing with SFK_pY416 antibody detects a 60-kDa band in all patient samples that were SFK_pY416+ by IHC (lanes 4 and 8 to 13) and does not detect the band in patient samples that were SFK_pY416− by IHC. Cleaved CDCP1_pY734, CDCP1_pY743, and SFK_pY527 are co-expressed with SFK_pY416. Whole cell lysate from the TNBC cell line MDA-MB-231 was used as a positive control (lane 1). TNBC-2 (lane 4) has granular cytoplasmic staining for SFK_pY416. All other SFK_pY416+ tumors had membrane staining. Equal amounts of protein were loaded to each lane, as quantitated by tryptophan fluorescence spectrometry. β-Actin was used as a loading control. B: Analysis of TNBC proteome in silico showing top eight proteins (protein names displayed next to data point) whose expression is correlated with SFK_pY416, with SFK_pY527 exhibiting the strongest correlation. TNBC tumor samples were isolated from The Cancer Proteome Atlas (TCPA) breast cancer (BRCA) data set by negativity for estrogen receptor, progesterone receptor, and human epidermal growth factor 2 receptor and analyzed for correlation of protein markers. Correlations were derived by Pearson product moment correlation test. cCDCP1, cleaved CDCP1; EGFR, epidermal growth factor receptor; FASN, fatty acid synthase; flCDCP1, full-length CDCP1; MEK1, dual specificity mitogen-activated protein kinase kinase 1; NFKBp65, nuclear factor NF-kappa-B p65 subunit; PEA15, astrocytic phosphoprotein PEA-15; RAB25, Ras-related protein rab-25; SFK, Src family kinase; SHP2, Src homology region 2–containing protein tyrosine phosphatase; STAT3, signal transducer and activator of transcription 3.

    Article Snippet: Antibody dilutions for each method are listed in . table ft1 table-wrap mode="anchored" t5 caption a7 Antigen Antibody information, manufacturer/catalog no. Western blot dilution IHC dilution Antigen retrieval ∗ FOXA1 Abcam/ab173287 NA 1:4000 1 Vimentin Agilent/M0725 NA 1:2000 2 Sox10 Bio SB/BSB2583 NA 1:100 1 CK5/6 Thermo Fisher Scientific/180267 NA 1:50 2 CDCP1 Cell Signaling Technology/4115 1:1000 1:100 1 CDCP1_pY743 Cell Signaling Technology/14965 1:1000 1:800 1 CDCP1_pY734 Cell Signaling Technology/9050 1:1000 NA NA Src Cell Signaling Technology/2108 1:1000 NA NA Lck Cell Signaling Technology/2752 1:1000 NA NA Lyn Cell Signaling Technology/2732 1:1000 NA NA SFK_pY416 Cell Signaling Technology/2101 1:1000 1:200 1 SFK_pY527 Cell Signaling Technology/2105 1:1000 NA NA PKCδ Cell Signaling Technology/2058 1:1000 NA NA PKCδ_pY311 Abcam/ab76181 1:2500 1:3000 1 N-cadherin Cell Signaling Technology/13116 NA 1:200 1 Slug Cell Signaling Technology/9585 NA 1:100 1 AMPKα Cell Signaling Technology/2532 1:1000 NA NA AMPKα_pT172 Cell Signaling Technology/2535 1:1000 NA NA β-Actin Leica Biosystems/A5441 1:5000 NA NA CD3 Novocastra/NCL-L-CD3-565 NA 1:50 2 PD1 Cell Signaling Technology/86163 NA 1:200 2 PD-L1 Cell Signaling Technology/13684 NA 1:400 2 CTLA4 Santa Cruz Biotechnology/sc-376016 NA 1:400 2 Open in a separate window AMPK, AMP-activated protein kinase; CDCP, CUB-domain containing protein; CK5/6, cytokeratin 5/6; CTLA4, cytotoxic T-lymphocyte protein 4; FOXA1, forkhead box protein A1; IHC, immunohistochemistry; Lck, tyrosine-protein kinase Lck; Lyn, tyrosine-protein kinase Lyn; NA, not applicable; PD1, programmed cell death protein 1; PD-L1, programmed cell death 1 ligand 1; PKC, protein kinase C; Sox10, Sry-box transcription factor 10.

    Techniques: Western Blot, Expressing, Immunohistochemistry, Positive Control, Staining, Fluorescence, In Silico, Isolation, Derivative Assay

    Western blot analysis of SFK_pY416− triple-negative breast cancer (TNBC) reveals that forkhead box protein 1 (FOXA1)+ samples tend to be SFK_pY527+ and FOXA1− samples tend to be SFK_pY527−. Paraffin sections of TNBC were extracted and analyzed by standard Western blot analysis technique. FOXA1, vimentin, and SFK_pY416 expression levels in tumor cells, as determined by immunohistochemistry (IHC), are summarized on top. A: All FOXA1+/SFK_pY416− samples tested were SFK_pY527+. The presence of SFK_pY416 in lanes 2, 4, and 6 is due to the presence of SFK_pY416+ lymphocytes in these tumor samples (shown in Supplemental Figure S1). B: Five of six FOXA1−/SFK_pY416− samples tested were SFK_pY527− (lanes 2, 3, and 5 to 7). Three FOXA1−/SFK_pY416+ tumor samples were run as controls. All samples contain phosphorylated AMP-activated protein kinase alpha (AMPKα) as a uniformly phosphorylated control for phosphoprotein extraction. Equal amounts of protein were loaded to each lane, as quantitated by tryptophan fluorescence spectrometry. β-Actin was used as a loading control. cCDCP1, cleaved CDCP1; CDCP1, CUB-domain containing protein 1; flCDCP1, full-length CDCP1; PKC, protein kinase C.

    Journal: The American Journal of Pathology

    Article Title: Src Kinase Is Biphosphorylated at Y416/Y527 and Activates the CUB-Domain Containing Protein 1/Protein Kinase C δ Pathway in a Subset of Triple-Negative Breast Cancers

    doi: 10.1016/j.ajpath.2019.10.017

    Figure Lengend Snippet: Western blot analysis of SFK_pY416− triple-negative breast cancer (TNBC) reveals that forkhead box protein 1 (FOXA1)+ samples tend to be SFK_pY527+ and FOXA1− samples tend to be SFK_pY527−. Paraffin sections of TNBC were extracted and analyzed by standard Western blot analysis technique. FOXA1, vimentin, and SFK_pY416 expression levels in tumor cells, as determined by immunohistochemistry (IHC), are summarized on top. A: All FOXA1+/SFK_pY416− samples tested were SFK_pY527+. The presence of SFK_pY416 in lanes 2, 4, and 6 is due to the presence of SFK_pY416+ lymphocytes in these tumor samples (shown in Supplemental Figure S1). B: Five of six FOXA1−/SFK_pY416− samples tested were SFK_pY527− (lanes 2, 3, and 5 to 7). Three FOXA1−/SFK_pY416+ tumor samples were run as controls. All samples contain phosphorylated AMP-activated protein kinase alpha (AMPKα) as a uniformly phosphorylated control for phosphoprotein extraction. Equal amounts of protein were loaded to each lane, as quantitated by tryptophan fluorescence spectrometry. β-Actin was used as a loading control. cCDCP1, cleaved CDCP1; CDCP1, CUB-domain containing protein 1; flCDCP1, full-length CDCP1; PKC, protein kinase C.

    Article Snippet: Antibody dilutions for each method are listed in . table ft1 table-wrap mode="anchored" t5 caption a7 Antigen Antibody information, manufacturer/catalog no. Western blot dilution IHC dilution Antigen retrieval ∗ FOXA1 Abcam/ab173287 NA 1:4000 1 Vimentin Agilent/M0725 NA 1:2000 2 Sox10 Bio SB/BSB2583 NA 1:100 1 CK5/6 Thermo Fisher Scientific/180267 NA 1:50 2 CDCP1 Cell Signaling Technology/4115 1:1000 1:100 1 CDCP1_pY743 Cell Signaling Technology/14965 1:1000 1:800 1 CDCP1_pY734 Cell Signaling Technology/9050 1:1000 NA NA Src Cell Signaling Technology/2108 1:1000 NA NA Lck Cell Signaling Technology/2752 1:1000 NA NA Lyn Cell Signaling Technology/2732 1:1000 NA NA SFK_pY416 Cell Signaling Technology/2101 1:1000 1:200 1 SFK_pY527 Cell Signaling Technology/2105 1:1000 NA NA PKCδ Cell Signaling Technology/2058 1:1000 NA NA PKCδ_pY311 Abcam/ab76181 1:2500 1:3000 1 N-cadherin Cell Signaling Technology/13116 NA 1:200 1 Slug Cell Signaling Technology/9585 NA 1:100 1 AMPKα Cell Signaling Technology/2532 1:1000 NA NA AMPKα_pT172 Cell Signaling Technology/2535 1:1000 NA NA β-Actin Leica Biosystems/A5441 1:5000 NA NA CD3 Novocastra/NCL-L-CD3-565 NA 1:50 2 PD1 Cell Signaling Technology/86163 NA 1:200 2 PD-L1 Cell Signaling Technology/13684 NA 1:400 2 CTLA4 Santa Cruz Biotechnology/sc-376016 NA 1:400 2 Open in a separate window AMPK, AMP-activated protein kinase; CDCP, CUB-domain containing protein; CK5/6, cytokeratin 5/6; CTLA4, cytotoxic T-lymphocyte protein 4; FOXA1, forkhead box protein A1; IHC, immunohistochemistry; Lck, tyrosine-protein kinase Lck; Lyn, tyrosine-protein kinase Lyn; NA, not applicable; PD1, programmed cell death protein 1; PD-L1, programmed cell death 1 ligand 1; PKC, protein kinase C; Sox10, Sry-box transcription factor 10.

    Techniques: Western Blot, Expressing, Immunohistochemistry, Fluorescence